文献速递物质与行为成瘾

药物治疗与苯丙胺使用障碍患者住院及死亡风险的关联:瑞典全国13 965例队列研究

Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients.
PubMed 文献 · JAMA Psychiatry · 2023-01-01

该瑞典全国注册队列纳入13 965例16–64岁首次诊断苯丙胺/甲基苯丙胺使用障碍且无精神分裂症或双相障碍者,随访中位3.9年,采用个体内模型比较17种药物使用与非使用期。 lisdexamphetamine使用与SUD住院、任何住院或死亡及全因死亡风险降低相关;苯二氮䓬类使用与三项结局风险升高相关;抗抑郁药和抗精神病药使用与SUD住院及任何住院或死亡风险轻度升高相关。

要点

  • lisdexamphetamine是唯一与三项结局风险降低均显著相关的药物。
  • 苯二氮䓬类使用与SUD住院、任何住院或死亡及全因死亡风险升高相关。
  • 抗抑郁药和抗精神病药使用与SUD住院及任何住院或死亡风险轻度升高相关。

核心结论

  • 在苯丙胺或甲基苯丙胺使用障碍患者中,lisdexamphetamine使用与住院和死亡结局改善相关,鼓励开展随机临床试验。
  • 处方苯二氮䓬类使用与不良结局相关。

研究设计与样本

  • 瑞典全国注册的基于人群队列研究,2006年7月至2018年12月,中位随访3.9年(IQR 1.0–6.1)。
  • 纳入16–64岁首次诊断苯丙胺或甲基苯丙胺使用障碍且既往无精神分裂症或双相障碍诊断的瑞典居民,共13 965人(男性9671人,69.3%;平均年龄34.4岁,SD 13.0)。
  • 采用PRE2DUP方法模拟药物使用期,主要结局采用个体内模型比较17种特定药物或药物类别的使用与非使用期,次要结局全因死亡采用个体间Cox模型。

主要发现

  • 随访期间,10 341人(74.0%)因SUD住院,11 492人(82.3%)因任何原因住院或死亡,1321人(9.5%)全因死亡。
  • lisdexamphetamine使用与SUD住院(aHR 0.82;95%CI 0.72–0.94)、任何住院或死亡(aHR 0.86;95%CI 0.78–0.95)及全因死亡(aHR 0.43;95%CI 0.24–0.77)风险降低相关。
  • 哌甲酯使用与全因死亡风险降低相关(aHR 0.56;95%CI 0.43–0.74)。
  • 苯二氮䓬类使用与SUD住院(aHR 1.17;95%CI 1.12–1.22)、任何住院或死亡(aHR 1.20;95%CI 1.17–1.24)及全因死亡(aHR 1.39;95%CI 1.20–1.60)风险升高相关。
  • 抗抑郁药使用与SUD住院(aHR 1.07;95%CI 1.03–1.11)及任何住院或死亡(aHR 1.10;95%CI 1.06–1.14)风险轻度升高相关;抗精神病药使用与SUD住院(aHR 1.05;95%CI 1.01–1.09)及任何住院或死亡(aHR 1.06;95%CI 1.03–1.10)风险轻度升高相关。

关键数值与推荐

  • lisdexamphetamine与SUD住院aHR 0.82(95%CI 0.72–0.94)、任何住院或死亡aHR 0.86(95%CI 0.78–0.95)、全因死亡aHR 0.43(95%CI 0.24–0.77)相关。
  • 哌甲酯与全因死亡aHR 0.56(95%CI 0.43–0.74)相关。
  • 苯二氮䓬类与SUD住院aHR 1.17(95%CI 1.12–1.22)、任何住院或死亡aHR 1.20(95%CI 1.17–1.24)、全因死亡aHR 1.39(95%CI 1.20–1.60)相关。
  • 抗抑郁药与SUD住院aHR 1.07(95%CI 1.03–1.11)、任何住院或死亡aHR 1.10(95%CI 1.06–1.14)相关。
  • 抗精神病药与SUD住院aHR 1.05(95%CI 1.01–1.09)、任何住院或死亡aHR 1.06(95%CI 1.03–1.10)相关。

临床怎么用

  • 在苯丙胺或甲基苯丙胺使用障碍患者中,lisdexamphetamine使用与住院和死亡结局改善相关,支持其在该人群中的潜在应用并鼓励随机临床试验验证。
  • 处方苯二氮䓬类与不良结局相关,临床应谨慎评估该人群的苯二氮䓬类使用。
  • 抗抑郁药和抗精神病药使用与SUD住院及任何住院或死亡风险轻度升高相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are no medications approved by authorities for the treatment of amphetamine or methamphetamine dependence, and studies investigating the effectiveness of pharmacological treatments in hard outcomes, such as hospitalization and death, are lacking. OBJECTIVE: To investigate the association between pharmacotherapies and hospitalization and mortality outcomes in persons with amphetamine or methamphetamine use disorder. DESIGN, SETTING, AND PARTICIPANTS: This nationwide register-based cohort study was conducted from July 2006 to December 2018 with a median (IQR) follow-up time of 3.9 (1.0-6.1) years. Data were analyzed from December 1, 2021, to May 24, 2022. All residents aged 16 to 64 years living in Sweden with a registered first-time diagnosis of amphetamine or methamphetamine use disorder and without previous diagnoses of schizophrenia or bipolar disorder were identified from nationwide registers of inpatient care, specialized outpatient care, sickness absence, and disability pension. EXPOSURES: Medications for substance use disorders (SUDs) or for attention-deficit/hyperactive disorder, mood stabilizers, antidepressants, benzodiazepines and related drugs, and antipsychotics. Medication use vs nonuse was modeled with the PRE2DUP (from prescription drug purchases to drug use periods) method. MAIN OUTCOMES AND MEASURES: Primary outcomes were hospitalization due to SUD and any hospitalization or death, which were analyzed using within-individual models by comparing use and nonuse periods of 17 specific medications or medication classes in the same individual to minimize selection bias. The secondary outcome was all-cause mortality, studied using between-individual analysis as traditional Cox models. RESULTS: There were 13 965 individuals in the cohort (9671 [69.3%] male; mean [SD] age, 34.4 [13.0] years). During follow-up, 7543 individuals (54.0%) were taking antidepressants, 6101 (43.7%) benzodiazepines, 5067 (36.3%) antipsychotics, 3941 (28.2%) ADHD medications (1511 [10.8%] were taking lisdexamphetamine), 2856 (20.5%) SUD medications, and 1706 (12.2%) mood stabilizers. A total of 10 341 patients (74.0%) were hospitalized due to SUDs, 11 492 patients (82.3%) were hospitalized due to any cause or died, and 1321 patients (9.5%) died of any cause. Lisdexamphetamine was the only medication in this study that was significantly associated with a decrease in risk of 3 outcomes (adjusted hazard ratio [aHR], 0.82; 95% CI, 0.72-0.94 for SUD hospitalization; aHR, 0.86; 95% CI, 0.78-0.95 for any hospitalization or death; aHR, 0.43; 95% CI, 0.24-0.77 for all-cause mortality). Methylphenidate use also was associated with lower all-cause mortality (aHR, 0.56; 95% CI, 0.43-0.74). Use of benzodiazepines was associated with a significantly higher risk of SUD hospitalization (aHR, 1.17; 95% CI, 1.12-1.22), any hospitalization or death (aHR, 1.20; 95% CI, 1.17-1.24), and all-cause mortality (aHR, 1.39; 95% CI, 1.20-1.60). Use of antidepressants or antipsychotics was associated with a slight increase in risk of SUD hospitalization (aHR, 1.07; 95% CI, 1.03-1.11 and aHR, 1.05; 95% CI, 1.01-1.09) as well as any hospitalization or death (aHR, 1.10; 95% CI, 1.06-1.14 and aHR, 1.06; 95% CI, 1.03-1.10, respectively). CONCLUSIONS AND RELEVANCE: In this study, use of lisdexamphetamine was associated with improved outcomes in persons with amphetamine or methamphetamine use disorders, encouraging the conduct of randomized clinical trials. Prescription benzodiazepine use was associated with poor outcomes.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hartikainen M, Taipale H, Tanskanen A, et al. Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients. JAMA Psychiatry. 2023. PMID: 36383348. doi:10.1001/jamapsychiatry.2022.3788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。